BioSpace News Archive

Amicus Therapeutics today announced that it has entered into a definitive agreement for a $430 million financing collaboration with funds managed by Blackstone Life Sciences and Blackstone Credit have agreed to provide Amicus with a $400 million senior secured term loan facilitating a refinancing of existing debt and a $30 million strategic investment in Amicus’s common stock.

Hoth Therapeutics, Inc. today announced the Pre-IND meeting requested on September 8th for HT-KIT with the U.S. Food and Drug Administration (FDA) has been granted to receive written responses only from the FDA that are targeted for delivery on November 7, 2023.

Eli Lilly and Company announced that the U.S. Food and Drug Administration has issued a complete response letter for the lebrikizumab biologic license application for the treatment of moderate-to-severe atopic dermatitis.

Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, announced eight data presentations (from an Attralus sponsored trial and from four investigator-initiated trials) related to the use of 124I-evuzamitide (AT-01), the company’s pan-amyloid binding imaging agent in development for the diagnosis and management of all types of systemic amyloidosis.

Kraig Biocraft Laboratories, Inc., the biotechnology company focused on the development and commercialization of spider silk, announced a shakeup of the management of its Vietnamese subsidiary, Prodigy Textiles.

Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced completion of initial analysis of OLINVYK continuous respiratory monitoring data from the VOLITION study.

Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the Japanese Patent Office has granted Compugen a patent for treating cancer with a triple combination of any anti- PVRIG antibody with any anti-TIGIT and anti-PD-1 antibody.

Newron Pharmaceuticals S.p.A. announced that Margarita Chavez has been appointed as an advisor to the Board of Directors of Newron, bringing significant pharmaceutical business development and dealmaking expertise.

Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea and related disorders, announced the appointment of Paul Fonteyne, MS, MBA, to its Board of Directors as an Independent Director.

Ascendis Pharma A/S presented a poster with results of a sub-analysis of its Phase 3 PaTHway clinical trial data during the recent American Thyroid Association annual meeting, showing that 81% of adults with chronic post-surgical hypoparathyroidism treated with TransCon PTH achieved independence from conventional calcium and active vitamin D therapy while maintaining normal serum calcium levels during the 26-week blinded portion of the trial, compared to 6% taking placebo.